5) $5b NY project: The bidding process for the three new licenses to operate a full-fledged casino in or around New York City will likely be one of the most hotly contested in U.S history, with many of the nation’s most prominent operators having already expressed interest.
Can you provide more details.. and the reasons behind considering it a poor investment decision?
I think miami land appreciated by multiple folds so its good. Just that interest cost too high now, hard to demand immediate single lump sum large payment from buyer for such a large piece of land.
NYC usd5b investment bopian leh, if can secure one of the 3 NYC licence, shd be able work out well in long run especially IPO potential.
Let's forget about TauRx, currently buy on pullback Genting for better YoY and QoQ of Revenue and profit 1stQ 24 Genting Singapore, better YoY and QoQ Revenue and profit 1stQ 24 Genting Malaysia, poorer YoY and QoQ of Revenue and profit 1stQ 24 Genting Plantation............
Not!! I do hope heartily taurx works. Or else, our $ gone. Just like sifu said. He should be perform a fantastic show to us before his retirement.... As I said, if Lim could put more concerns on minority shareholders, He will gain my respect. 👍
US and Japanese market are expected to start a correction in 1-2 weeks time until a suitable timing for US to start an election bull run. Bursa is struggling to start a Raya bull but not sure if can be successful (if KLCI can be supported above 1520 by local fund). Genting technically is good at last Friday to start a short breakout because currently share price is above ceiling of long term downtrend channel @4.88 and also above MAV20. MACD hooked up from neutral touching signal but haven't crossed, Stochastic %K %D is above smooth %D and above 50%, RSI is @50%, hopefully tomorrow is at least a doji and closed above 4.88 then breakout can be maintained
GENM also state a techinical buy signal as follows: https://www.youtube.com/watch?v=aZZKycFZnbs However Genting chart is technically more beautiful than GENM as long as Genting can stay above 4.88 these coming few days
The main issue with Taurx is that placebo cannot be used as a comparator. I thought scientifically it can be proven that the drug is effective. Can’t see if additional testing will resolve this issue. The data gathered so far is conclusive…and given its safety profile there is a strong case for approval. Also there is a precedent where approval has been given without a placebo comparator …hopefully the regulators are convinced. On balance there is strong case for approval to be given unless of course politics is in play, which can never be discounted. I feel very positive of the outcome however I impact on Gent price and major shareholder behaviour is the major unknown…still risk / reward ratio is positive
US and Japanese market has been the leaders so far this year. With Japan delivering whopping 43 % return and US 27 % circa return this year, even Europe has been positive. What is worrying is we continue to underperform and when US correction happens which is due, we will follow the correction downwards but never upwards! China and HK is struggling and this needs to reverse, most likely 2025.
Short term target around 5.40. Slow Slow will be better...... Checked Bursa Nett Short position no Genting share but only GENM. (From Jan to March chart, Fund in control big wash weak holders 2 times and small wash numerous times, only push over RM5 at 3rd attempts. 3rd attempt is pushed only after hot money escaped with planned " disappointed" QR. Therefore 4.90-5 will be strong support for Genting share price. After hitting 5.40, if share price can form a flag again, ranging 5.40-5 thus from 5+0.72=5.72 as next target.) (Despite many times wrong prediction, technically we can see that Genting 1st leg is 4.74-4.02=0.72 (November 23), after that it enter less reliable flag pattern until MACD reaching neutral zone, stochastic reaching oversold zone yesterday. With today rebound, RSI hook up almost reaching 50% and Stochatic %K %D crossed smoothed %D. Again if 4.90 resistance can be crossed and stay more than 3 days, chances is 2nd leg 4.65+0.72=5.37 may be targeted. Any gap up above 5.40..........)
We are pleased to confirm receipt of investigative new drug (IND) approval from the National Medical Products Administration (NMPA) in China for study TRx-237-801. dMed-Clinipace, a global CRO based in Shanghai, has been selected as the research partner for this study. We estimate that 60% of the global burden of AD is in Asian countries compared with only 12% in Europe and US combined.
Genting’s target price could be raised to as high as RM9.40 under a blue sky scenario, where HMTM is approved and TauRx is valued at US$15 billion (RM70.3 billion) without discount, the research house added.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Michael_chan2022
3,349 posts
Posted by Michael_chan2022 > 2024-03-10 19:06 | Report Abuse
5) $5b NY project:
The bidding process for the three new licenses to operate a full-fledged casino in or around New York City will likely be one of the most hotly contested in U.S history, with many of the nation’s most prominent operators having already expressed interest.
Can you provide more details.. and the reasons behind considering it a poor investment decision?